Your session is about to expire
← Back to Search
Mindfulness Training for Hidradenitis Suppurativa
N/A
Recruiting
Led By Hadar Lev-Tov, MD
Research Sponsored by University of Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Individuals below the age of 18 years old
Adults unable to consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to see if mindfulness training can improve quality of life for those with HS, a skin condition causing inflammation and pain.
Who is the study for?
This trial is for adults with Hidradenitis Suppurativa (HS) who are registered at the University of Miami Hospital dermatology system. Participants must speak English and be able to consent. It's not for those under 18, pregnant women, prisoners, individuals with active drug addictions, psychosis or suicidal thoughts, or untreated PTSD.
What is being tested?
The study is testing whether a mindfulness training course can improve the quality of life in HS patients compared to an educational course about HS. Patients will learn techniques aimed at reducing stress and improving mental well-being.
What are the potential side effects?
Mindfulness training generally does not have direct physical side effects but may bring up emotional discomfort as participants become more aware of their thoughts and feelings.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am under 18 years old.
Select...
I am unable to give consent for myself.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 10 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
HS Quality of Life Measure (HiSQOL) Scores
Secondary study objectives
Dermatology Life Quality Index (DLQI) Scores
Five-Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) Scores
Hidradenitis Suppurativa Physician's Global Assessment Scale (HS-PGA) Scores
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Mindfulness Course GroupExperimental Treatment1 Intervention
Participants will participate in the mindfulness course that would last 6 weeks.
Group II: HS Educational Course GroupExperimental Treatment1 Intervention
Participants will participate in the mindfulness course that would last 6 weeks.
Find a Location
Who is running the clinical trial?
University of MiamiLead Sponsor
955 Previous Clinical Trials
428,823 Total Patients Enrolled
4 Trials studying Hidradenitis Suppurativa
105 Patients Enrolled for Hidradenitis Suppurativa
Hadar Lev-Tov, MDPrincipal InvestigatorUniversity of Miami
8 Previous Clinical Trials
200 Total Patients Enrolled
4 Trials studying Hidradenitis Suppurativa
105 Patients Enrolled for Hidradenitis Suppurativa
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am under 18 years old.People who are being treated for Hidradenitis Suppurativa at the University of Miami Hospital dermatology department.I am unable to give consent for myself.You are currently struggling with drug addiction.You have severe mental health issues like hallucinations or thoughts about hurting yourself.You have untreated PTSD.I currently have tumors or lesions.
Research Study Groups:
This trial has the following groups:- Group 1: Mindfulness Course Group
- Group 2: HS Educational Course Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.